Indian Biotechnology Industry Analysis #pharma #job #search

Posted On Aug 12 2017 by

#biotechnology industry


Indian Biotechnology Industry Analysis

Robust growth in Biotech industry

Maintaining the momentum of the previous years, the Indian biotech industry grew 16.28 per cent in FY14; the total industry size was US$ 5 billion at the end of the financial year and it reached US$ 7 billion in FY15.

Fast-paced growth is likely to continue; the industry is expected to increase in size to USD11.6 billion by 2017, driven by a range of factors such as growing demand, intensive R D activities and strong government initiatives

Bio-pharma accounts for majority market share

The bio-pharmaceutical segment accounted for the largest share of the biotech industry, with 62.0 per cent of total revenues in FY15. Revenue from bio-pharma exports reached US$ 2.2 billion in 2013, accounting for 51 per cent of total revenues of the biotech industry.

The bio-services segment recorded the highest growth 11.78 per cent in FY14, followed by bio-informatics (7.9 per cent) and biopharma (6.23 per cent).

Last Updated: January, 2016

India is among the top 12 biotech destinations in the world and ranks second in Asia, after China. The Indian biotech industry is likely to experience significant growth on the back of increasing economic prosperity, health consciousness and a billion-plus population base. Current estimates value the industry at US$ 7 billion in FY15, which is expected to grow at 30.46 per cent Compound Annual Growth Rate (CAGR) to US$ 100 billion by FY25.

The sector is divided into five major segments: bio-pharma, bio-services, bio-agri, bio-industrial and bio-informatics. Biotechnology industry s growth in India is primarily driven by vaccines and recombinant therapeutics. Going forward, India also has the potential to become a major producer of transgenic rice and several Genetically Modified (GM) or engineered vegetables.

The Government of India has taken several initiatives including a biotechnology industry partnership program to develop new technologies and launched a National Rural Healthcare Mission to boost healthcare spending. As per the 12th Five-Year Plan, the government aims to spend US$ 3.7 billion on biotechnology compared to US$ 1.1 billion in the 11th Five-Year Plan to accelerate the pace of research, innovation and development. In addition, the Department of Biotechnology (DBT) has designed the National Biotechnology Development Strategy (NBDS) to strengthen the industry s human resources and infrastructure while promoting growth and trade. Furthermore, the Government has allowed 100 per cent Foreign Direct Investment (FDI) through the automatic route for manufacturers of drugs and pharmaceuticals.

Sectoral Presentation (January, 2016)


Related NewsMore

Last Updated: August 16, 2016

  • Rules eased to import, export human biological samples
  • Boston Scientific to make India biggest product development hub outside US
  • Pepsi, Monsanto to set up units in Maharashtra
  • Karnataka govt to raise Rs 50 crore as biotech fund
  • Pharma department to launch Rs 1,000-cr VC for pharma start-ups

The Indian biotech industry is expected to reach US$ 11.6 billion by 2017.

Biotechnology India

Biotechnology Clusters

Industry Contacts



The Indian biotechnology sector is expected to clock US$ 10 billion in revenue by 2015 on the back of emerging opportunities from around the world.

IBEF Publications

India Now Magazine

India Now Business and Economy

Powered by the Who’s Who of India

India: Unlocking our skies

Dr. Shobhit Jain, IRS, Deputy CEO IBEF

In a major boost to regional air connectivity, the Government of India has recently announced that it plans to set up 50 new airports in the country over the next three y.

GST: Great Step of Transformation

Ravi Capoor, IAS, Chief Executive Officer, IBEF

The much-awaited Constitution Amendment Bill for Goods and Services Tax (GST) was passed in the Parliament recently and is expected to be implemented by April 2017 replac.

Making SMEs bankable and banking on SMEs

Mr. R. Narayan, Founder & CEO, Power2SME

India is considered a bright spot in the gloomy, global economic scenario today. The country with a GDP growth of 7.6% (in 2015-16) has topped the World Bank’.

Brand India Engineering at INNOPROM 2016

Ravi Capoor, IAS, Chief Executive Officer, IBEF

India successfully showcased its strengths in the field of engineering at the flagship Russian international trade fair, INNOPROM 2016 held at Yekaterinburg, Russia from.

How is OYO catering to the changing needs of Millennials

Ritesh Agarwal, ‎Founder & CEO, OYO Rooms

As we see one of the largest generation in the history move into the earning and then spending stage in their lives, it is imperative that marketers understand the behavi.

India: The most open economy for FDI

Ravi Capoor, IAS, Chief Executive Officer, IBEF

The Government of India has recently announced radical liberalisation of the Foreign Direct Investment (FDI) regime by easing norms for a host of important sectors includ.

ideas More

A Big Step Forward
Krispian Lawrence co-founded Ducere Technologies with Anirudh Sharma in 2011. Lechal is the outcome of their concerted efforts to use haptics in the wearable technology space. Both Anirudh and I were always fascinated by wearable technology, and were tinkering with various ideas in this space. But the concept was nascent.


Last Updated on: August 11th, 2017 at 11:50 pm, by

Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *